## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA PHARM Form 4 March 13, 2007	MACEUTIC	CALS INC	2							
FORM 4								OMB A	PPROVAL	
	UNITED	STATES					E COMMISSIO	N OMB Number:	3235-0287	
Washington, D.C. 20549         Check this box       if no longer         subject to       STATEMENT OF CHANGES IN BENEFICIAL OF         Section 16.       SECURITIES         Form 4 or       Form 4 or							Expires: January			
Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Section 17(	a) of the l	Public U	Jtility Ho	lding Cor		nge Act of 1934, a of 1935 or Secti 1940	·		
(Print or Type Respon	nses)									
1. Name and Address of Reporting Person <u>*</u> Lundstrom Brian			2. Issuer Name <b>and</b> Ticker or Trading Symbol ACADIA PHARMACEUTICALS			5. Relationship of Reporting Person(s) to Issuer				
			INC [A	CAD]			(Che	eck all applicabl	e)	
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year)			Director X Officer (gi below)		% Owner her (specify		
3911 SORRENTO VALLEY BOULEVARD			03/09/2007				Sr. VP, Bus. Devt.			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
SAN DIEGO, CA							Person	More than One K	eporting	
(City) (	State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	nnsaction Date th/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	or (D) Price	Transaction(s) (Instr. 3 and 4)			
Reminder: Report on	a separate line	for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					Perso inforn requir	ns who res nation con red to resp nys a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tabl					posed of, or convertible	• Beneficially Owned securities)	d		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	orDerivative	Expiration Date	Underlying Securities	]

8 E

## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	(Month/Day	/Year)	(Instr. 3 and	4)	
				Code V	(A) (D	) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 6.86	03/09/2007		А	17,750	<u>(1)</u>	03/08/2017	Common Stock	17,750	
Repo	orting Ov	wners								
1	Reporting Owne	er Name / Address	Director	10% Owi	<b>Relationship</b> ner Officer	s	Other			
Lundstro	om Brian									

Sr. VP, Bus. Devt.

SAN DIEGO, CA 92121 Signatures

/s/ Uli Hacksell, Attorney-in-Fact	03/13/2007		
**Signature of Reporting Person	Date		

3911 SORRENTO VALLEY BOULEVARD

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the Stock Option vest and become exercisable on March 9, 2008. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

C